Found 387 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
UPCC 32922: A Phase 1 First-in-Human Study of IK-930 an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Please refer to Protocol, Section 1.1.3. (Study Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints)
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC)
This phase II trial studies how well avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like …
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
This trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug …
RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
Defining the role of germline genetic variants in gastric cancer tumorigenesis
The research study is being conducted to better understand factors that lead to gastric (stomach) cancer, including differences in our genes that may put some people at increased risk of developing gastric cancer compared to other people. Both people with increased risk as well as people with average risk of …
Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer
To study whether fulvestrant is more effective than anastrozole or tamoxifen in reducing Ki67 in ILC and whether that Ki67 reduction will correlate with alterations in expression of ER and ER-regulated genes. Differential Ki67 effect in this study will serve as a surrogate for outcome of ILC patients on endocrine …
Testing novel drugs or drug combinations to treat breast cancer before surgery
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
Please choose between Voice or SMS based delivery of verification code
or